Results 31 to 40 of about 28,700 (297)

Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas

Frontiers in Oncology, 2018
Objective: Infantile hemangiomas (IHs) are the most common vascular tumors of infancy. Oral propranolol has achieved great success in treating IHs since 2008.
H. Wu, Xuan Wang, Ling Zhang, Jia-wei Zheng, Chao Liu, Yan An Wang   +5 more
semanticscholar   +1 more source

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds.

Advances in wound care, 2019
Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap.
A. Gallegos, M. J. Davis, C. Tchanque-Fossuo, K. West, A. Eisentrout-Melton, T. Peavy, R. Dixon, Roma P. Patel, S. Dahle, R. Isseroff   +9 more
semanticscholar   +1 more source

Effects of 0.5% Timolol Maleate Ophthalmic Solution on Heart Rate and Selected Echocardiographic Indices in Apparently Healthy Cats

Journal of Veterinary Internal Medicine, 2016
Background Echocardiographic assessment of diastolic function is challenging in cats, partially because of transmitral flow pattern fusion associated with high heart rates.
C.T. Gunther‐Harrington, E.S. Ontiveros, T.E. Hodge, L.C. Visser, J.A. Stern   +4 more
doaj   +1 more source

A comparative evaluation of efficiency of fixed combination hypotensives for the treatment of primary open-angle glaucoma

Российский офтальмологический журнал, 2018
Purpose. To compare hypotensive efficiency and safety of fixed combinations of drugs treating primary open-angle glaucoma (POAG). Material and methods.
F. A. Bakhritdinova, S. Sh. Mirrakhimova, U. R. Karimov, A. . Khera   +3 more
doaj   +1 more source

Topical prostaglandin analogues and conjunctival inflammation in uveitic glaucoma. [PDF]

, 2012
A pilot study to determine whether topical prostaglandin analogues alter the expression of conjunctival inflammatory markers in patients with uveitic glaucoma.Prospective, single-masked case series of 20 patients with uveitis and secondary raised ...
Gurbaxani, A, Lightman, S, Sallam, A, Taylor, SR   +3 more
core   +1 more source

Daylight-Mediated, Passive, and Sustained Release of the Glaucoma Drug Timolol from a Contact Lens

ACS Central Science, 2018
Timolol, a potent inhibitor of β-adrenergic receptors (βARs), is a first-line drug for decreasing the intraocular pressure (IOP) of patients with glaucoma.
Changhua Mu, Meng Shi, Ping Liu, Lu Chen, G. Marriott   +4 more
semanticscholar   +1 more source

Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination [PDF]

, 2010
To compare the ocular hypotensive effect of bimatoprost plus timolol and travoprost plus timolol fixed combinations in glaucoma patients whose disease was controlled but had not reached their target intraocular pressure (IOP) with the fixed combination ...
Boehm, A, Centofanti, M, Gandolfi, S, Haustein, M, Hommer, A, Manni, G, Oddone, F, Rossetti, L, Sangermani, C, Sportelli, V, Tanga, L   +10 more
core   +2 more sources

TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

Pharmaceutics, 2022
To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol.
Kornelia E. C. Andorfer, Florian Zeman, Michael Koller, Judith Zeller, René Fischer, Caroline T. Seebauer, Veronika Vielsmeier, Christopher Bohr, Thomas S. Kühnel   +8 more
doaj   +1 more source

Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study. [PDF]

, 2020
Background:Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the ...
Cioffi, George A, Feldman, Robert M, Feldman, Robert M, Liebmann, Jeffrey M, Weinreb, Robert N   +4 more
core  

Study on the safety profile of Latanoprost and Timolol in primary open angle glaucoma [PDF]

, 2016
Background: Topical beta blockers, Timolol and the prostaglandin F2α analogue Latanoprost are the most common prescribed medications as first line therapy. Their safety profiles have to be compared to justify the same.
Narayanan, P. V., Rao, Sharadashri
core   +2 more sources